ARQT vs. LEGN, GRFS, TLX, TGTX, LNTH, NUVL, AXSM, AKRO, PCVX, and ADMA
Should you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Legend Biotech (LEGN), Grifols (GRFS), Telix Pharmaceuticals (TLX), TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.
Arcutis Biotherapeutics vs. Its Competitors
Arcutis Biotherapeutics (NASDAQ:ARQT) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.
In the previous week, Arcutis Biotherapeutics and Arcutis Biotherapeutics both had 6 articles in the media. Legend Biotech's average media sentiment score of 1.44 beat Arcutis Biotherapeutics' score of 1.18 indicating that Legend Biotech is being referred to more favorably in the news media.
Arcutis Biotherapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.
70.9% of Legend Biotech shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Arcutis Biotherapeutics has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Arcutis Biotherapeutics presently has a consensus target price of $18.80, indicating a potential upside of 36.92%. Legend Biotech has a consensus target price of $74.18, indicating a potential upside of 106.32%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Arcutis Biotherapeutics.
Legend Biotech has a net margin of -29.95% compared to Arcutis Biotherapeutics' net margin of -60.95%. Legend Biotech's return on equity of -21.19% beat Arcutis Biotherapeutics' return on equity.
Summary
Legend Biotech beats Arcutis Biotherapeutics on 11 of the 15 factors compared between the two stocks.
Get Arcutis Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcutis Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ARQT) was last updated on 7/2/2025 by MarketBeat.com Staff
